Results: 3

1.
Figure 1

Figure 1. From: Randomized, Placebo-Controlled, Clinical Trial of Donepezil in Vascular Dementia.

Decision tree for classifying patients as having possible vs probable VaD. CT indicates computed tomography; CVD, cardiovascular disease; and NINDS-AIREN, National Institute of Neurological Disorders and Stroke–Association Internationale pour la Recherche et l’Enseignement en Neurosciences.

Gustavo C. Román, et al. Stroke. ;41(6):1213-1221.
2.
Figure 3

Figure 3. From: Randomized, Placebo-Controlled, Clinical Trial of Donepezil in Vascular Dementia.

Primary outcome measures in donepezil and placebo patients. A, V-ADAS-cog least-squares (LS) mean change from baseline; B, CIBIC-Plus overall change at end point. C, V-ADAS-cog LS mean change from baseline for patients with Scheltens’ score <2. D, V-ADAS-cog LS mean change from baseline for patients with Scheltens’ score ≥2. CMH indicates Cochran-Mantel-Haenszel; LOCF, last observation carried forward.

Gustavo C. Román, et al. Stroke. ;41(6):1213-1221.
3.
Figure 2

Figure 2. From: Randomized, Placebo-Controlled, Clinical Trial of Donepezil in Vascular Dementia.

Flowchart of patients excluded from the study and included patients randomized to active treatment with 5 mg/d donepezil or placebo. TIA indicates transient ischemic attack. *Patients might have >1 reason for screen failure, and some patients were screened more than once. Twenty-five patients were excluded from the ITT population because they did not have a baseline assessment in addition to at least 1 postbaseline assessment for at least 1 of the primary efficacy variables. Eleven patients died during the study (all in the donepezil group).

Gustavo C. Román, et al. Stroke. ;41(6):1213-1221.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk